In -Vitro Study of Favipiravir Marketed 200 mg Tablets

Navdeep kaur

Favipiravir, In- vitro release, Disintegration, Marketed tablets.

The aim of work to evaluate the marketed tablets of favipiravir of Glenmark which is used for the treatment of covid-19 infection. Dose also varies according to company and firstly designed 200mg favipiravir for the treatment of influenza infection in Japan. Favipiravir is a modified pyrazine analogue and repurposed drug that targets RNA polymerase enzymes. At present, only the oral route is available in the form of tablets in higher doses. They were evaluated in the current studies, i.e., in-vitro drug release studies

Published Paper   E-Certificate

"In -Vitro Study of Favipiravir Marketed 200 mg Tablets", IJSDR - International Journal of Scientific Development and Research (www.IJSDR.org), ISSN:2455-2631, Vol.7, Issue 9, page no.446 - 448, September-2022, Available :https://ijsdr.org/papers/IJSDR2209075.pdf

Volume 7 Issue 9, September-2022

Pages : 446 - 448

Paper Reg. ID: IJSDR_201643

Published Paper Id: IJSDR2209075

Downloads: 000347235

Research Area: Pharmacy

Country: sirsa, Haryana, India

Published Paper PDF: https://ijsdr.org/papers/IJSDR2209075

Published Paper URL: https://ijsdr.org/viewpaperforall?paper=IJSDR2209075

DOI: http://doi.one/10.1729/Journal.31721

ISSN: 2455-2631 | IMPACT FACTOR: 9.15 Calculated By Google Scholar | ESTD YEAR: 2016

An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 9.15 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator

Publisher: IJSDR(IJ Publication) Janvi Wave

This work is licensed under a Creative Commons Attribution 4.0 International License and The Open Definition